J147 E-isomer

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H535043

CAS#: 1807913-16-1 (E-isomer)

Description: J-147 is an E-isomer of J147 (Cat#522384). J147 is a potent neuroprotective and neurotrophic compound. J147 protects against neurotoxicity in cortical neurons in vitro (EC50 = 25 - 200 nM). J147. J147 reverses cognitive impairment in aged Alzheimer's disease mice. J147 is an exciting new compound that is extremely potent, safe in animal studies and orally active. J147 is a potential AD therapeutic due to its ability to provide immediate cognition benefits, and it also has the potential to halt and perhaps reverse disease progression in symptomatic animals as demonstrated in these studies.


Chemical Structure

img
J147 E-isomer
CAS# 1807913-16-1 (E-isomer)

Theoretical Analysis

Hodoodo Cat#: H535043
Name: J147 E-isomer
CAS#: 1807913-16-1 (E-isomer)
Chemical Formula: C18H17F3N2O2
Exact Mass: 350.12
Molecular Weight: 350.341
Elemental Analysis: C, 61.71; H, 4.89; F, 16.27; N, 8.00; O, 9.13

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1417911-00-2 (C13-labeled)   1146963-51-0 (E/Z isomers)   1807913-16-1 (E-isomer)    

Synonym: J147 E-isomer; J-147; J 147; J147;

IUPAC/Chemical Name: Acetic acid, 2,2,2-trifluoro-, (2E)-1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene]hydrazide

InChi Key: HYMZAYGFKNNHDN-SSDVNMTOSA-N

InChi Code: InChI=1S/C18H17F3N2O2/c1-12-7-8-16(13(2)9-12)23(17(24)18(19,20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H,1-3H3/b22-11+

SMILES Code: O=C(N(C1=CC=C(C)C=C1C)/N=C/C2=CC=CC(OC)=C2)C(F)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 350.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Lapchak PA, Bombien R, Rajput PS. J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox™ Safety and Genotoxicity Analysis. J Neurol Neurophysiol. 2013 Aug;4(3):158. doi: 10.4172/2155-9562.1000158. PMID: 25364619; PMCID: PMC4215638.


2: Goldberg J, Currais A, Prior M, Fischer W, Chiruta C, Ratliff E, Daugherty D, Dargusch R, Finley K, Esparza-Moltó PB, Cuezva JM, Maher P, Petrascheck M, Schubert D. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018 Apr;17(2):e12715. doi: 10.1111/acel.12715. Epub 2018 Jan 7. PMID: 29316249; PMCID: PMC5847861.


3: Daugherty DJ, Marquez A, Calcutt NA, Schubert D. A novel curcumin derivative for the treatment of diabetic neuropathy. Neuropharmacology. 2018 Feb;129:26-35. doi: 10.1016/j.neuropharm.2017.11.007. Epub 2017 Nov 6. PMID: 29122628; PMCID: PMC5841546.


4: Currais A, Huang L, Goldberg J, Petrascheck M, Ates G, Pinto-Duarte A, Shokhirev MN, Schubert D, Maher P. Elevating acetyl-CoA levels reduces aspects of brain aging. Elife. 2019 Nov 19;8:e47866. doi: 10.7554/eLife.47866. PMID: 31742554; PMCID: PMC6882557.


5: Larrick JW, Larrick JW, Mendelsohn AR. ATP Synthase, a Target for Dementia and Aging? Rejuvenation Res. 2018 Feb;21(1):61-66. doi: 10.1089/rej.2018.2056. PMID: 29461942.


6: Schmitt D, Nill S, Roeder F, Herfarth K, Oelfke U. SU-E-J-147: Dosimetric Consequences of Intrafraction Prostate Motion: Comparison Between Phantom Measurements and Three Different Calculation Methods. Med Phys. 2012 Jun;39(6Part8):3686. doi: 10.1118/1.4734984. PMID: 28518909.


7: Farrán MÁ, Bonet MÁ, Claramunt RM, Torralba MC, Alkorta I, Elguero J. The structures of 1,4-diaryl-5-trifluoromethyl-1H-1,2,3-triazoles related to J147, a drug for treating Alzheimer's disease. Acta Crystallogr C Struct Chem. 2018 Apr 1;74(Pt 4):513-522. doi: 10.1107/S2053229618004394. Epub 2018 Mar 28. PMID: 29620036.


8: Prior M, Goldberg J, Chiruta C, Farrokhi C, Kopynets M, Roberts AJ, Schubert D. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. doi: 10.1016/j.jalz.2016.03.016. Epub 2016 May 2. PMID: 27149904; PMCID: PMC5349322.


9: Lian L, Xu Y, Zhang J, Yu Y, Zhu N, Guan X, Huang H, Chen R, Chen J, Shi G, Pan J. Antidepressant-like effects of a novel curcumin derivative J147: Involvement of 5-HT1A receptor. Neuropharmacology. 2018 Jun;135:506-513. doi: 10.1016/j.neuropharm.2018.04.003. Epub 2018 Apr 5. PMID: 29626566.


10: Currais A, Goldberg J, Farrokhi C, Chang M, Prior M, Dargusch R, Daugherty D, Armando A, Quehenberger O, Maher P, Schubert D. A comprehensive multiomics approach toward understanding the relationship between aging and dementia. Aging (Albany NY). 2015 Nov;7(11):937-55. doi: 10.18632/aging.100838. PMID: 26564964; PMCID: PMC4694064.


11: Chen HY, Xu DP, Tan GL, Cai W, Zhang GX, Cui W, Wang JZ, Long C, Sun YW, Yu P, Tsim KW, Zhang ZJ, Han YF, Wang YQ. A Potent Multi-functional Neuroprotective Derivative of Tetramethylpyrazine. J Mol Neurosci. 2015 Aug;56(4):977-987. doi: 10.1007/s12031-015-0566-x. Epub 2015 May 17. PMID: 25982925.


12: Kim K, Park KS, Kim MK, Choo H, Chong Y. Dicyanovinyl-substituted J147 analogue inhibits oligomerization and fibrillation of β-amyloid peptides and protects neuronal cells from β-amyloid-induced cytotoxicity. Org Biomol Chem. 2015 Oct 7;13(37):9564-9. doi: 10.1039/c5ob01463h. PMID: 26303522.


13: Clarkson GJ, Farrán MÁ, Claramunt RM, Alkorta I, Elguero J. The structure of the anti-aging agent J147 used for treating Alzheimer's disease. Acta Crystallogr C Struct Chem. 2019 Mar 1;75(Pt 3):271-276. doi: 10.1107/S205322961900144X. Epub 2019 Feb 12. PMID: 30833521.


14: Lv J, Cao L, Zhang R, Bai F, Wei P. A curcumin derivative J147 ameliorates diabetic peripheral neuropathy in streptozotocin (STZ)-induced DPN rat models through negative regulation AMPK on TRPA1. Acta Cir Bras. 2018 Jun;33(6):533-541. doi: 10.1590/s0102-865020180060000008. PMID: 30020315.


15: Emmanuel IA, Olotu FA, Agoni C, Soliman MES. Deciphering the 'Elixir of Life': Dynamic Perspectives into the Allosteric Modulation of Mitochondrial ATP Synthase by J147, a Novel Drug in the Treatment of Alzheimer's Disease. Chem Biodivers. 2019 Jun;16(6):e1900085. doi: 10.1002/cbdv.201900085. Epub 2019 May 28. PMID: 30990952.


16: Emmanuel IA, Olotu F, Agoni C, Soliman MES. Broadening the horizon: Integrative pharmacophore-based and cheminformatics screening of novel chemical modulators of mitochondria ATP synthase towards interventive Alzheimer's disease therapy. Med Hypotheses. 2019 Sep;130:109277. doi: 10.1016/j.mehy.2019.109277. Epub 2019 Jun 11. PMID: 31383337.


17: Chiruta C, Zhao Y, Tang F, Wang T, Schubert D. Metabolism of a potent neuroprotective hydrazide. Bioorg Med Chem. 2013 May 15;21(10):2733-41. doi: 10.1016/j.bmc.2013.03.020. Epub 2013 Mar 24. PMID: 23582448.


18: Walker EJ, Ralston GB, Darvey IG. Further evidence for an allosteric model for ribonuclease. Biochem J. 1976 Feb 1;153(2):329-37. doi: 10.1042/bj1530329. PMID: 1275891; PMCID: PMC1172578.


19: Walker EJ, Ralston GB, Darvey IG. The nature of the allosteric interactions of ribonuclease and its ligands. Biochem J. 1978 Jul 1;173(1):1-4. doi: 10.1042/bj1730001. PMID: 28730; PMCID: PMC1185741.


20: Wang M, Gao M, Zheng QH. The first synthesis of [11C]J147, a new potential PET agent for imaging of Alzheimer's disease. Bioorg Med Chem Lett. 2013 Jan 15;23(2):524-7. doi: 10.1016/j.bmcl.2012.11.031. Epub 2012 Nov 22. PMID: 23237833.